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osting by EAbstract Background: In-stent restenosis remains the major limitation of coronary stent implan-
tation. Leptin is a hormone strongly related to insulin resistance (IR). Moreover, insulin resistance
and hyperinsulinemia are common in patients with coronary heart disease (CHD), each of the pre-
vious metabolic and hormonal factors might be involved in restenosis after stent implantation.
Objective: This study was planned to evaluate the relationship between insulin resistance, insulin,
leptin levels and coronary in-stent restenosis after coronary stent implantation in non-diabetic
patients with CHD and to determine their value in prediction of restenosis.
Patients and methods: The study included 48 non-diabetic CHD patients with previous successful
coronary stent implantation. They were divided into two groups according to the presence of
in-stent restenosis on follow-up coronary angiography (6–9 months after stent implantation). The
ﬁrst group was CHD patients with in-stent restenosis which included 20 patients, the second group
was CHD patients without restenosis which included 28 patients. All patients were subjected to com-
plete clinical examination including determination of body mass index (BMI), waist to hip ratio
(WHR) and laboratory investigations including fasting plasma glucose (FPG), fasting plasma insulin
(FP insulin), lipid proﬁle (total cholesterol, HDL-C, LDL-C, TG), glycoselated hemoglobin (HbA1c),
plasma leptin, estimation of homeostasis model assessment of IR (HOMA-IR). All subjects were sub-
mitted to OGTT with estimation of 2-h post-prandial glucose (2-hPP glucose) and sum post-prandial
insulin levels (sum PP insulin). Follow-up coronary angiography was done for all patients with the
estimation of minimal luminal diameter (MLD), diameter stenosis % and late lumen loss..com (A. Shoukry).
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36 A. Shoukry et al.Results: There was highly signiﬁcant increase in each of FP insulin, sum PP insulin, HOMA-IR, lep-
tin, diameter stenosis % and late lumen loss (P< 0.001) and a highly signiﬁcant decrease of MLD
(P< 0.001) in CHD patients with in-stent restenosis when compared to CHD patients without in-
stent restenosis. MLD is negatively correlated to each of FP insulin (r= 0.49, P < 0.001), sum
PP insulin (r= 0.60, P < 0.001) HOMA-IR (r= 0.63, P < 0.001) and leptin (r= 0.55, P
< 0.001) while late lumen loss was positively correlated to each of FP insulin (r= 0.98, P
< 0.001), sum PP insulin (r= 0.70, P < 0.001), HOMA-IR (r= 0.67, P< 0.001) and leptin
(r= 0.72, P< 0.001). Multiple regression analysis revealed that each of FP insulin, sum PP insulin,
HOMA-IR and leptin can be considered an independent predictor of in-stent restenosis (P< 0.001).
Conclusion: Our study revealed that insulin resistance, fasting and post-prandial hyperinsulinemia
and hyperliptinemia are considered predictors of coronary in-stent restenosis. Evaluation of
HOMA-IR, insulin levels after standard OGTT and leptin levels are important tools in an attempt
to recognize subjects at risk of early restenosis among non-diabetic, CHD patients undergoing percu-
taneous coronary revascularization and stent implantation.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Intracoronary stenting is an accepted treatment for coronary ar-
tery stenosis or closure after percutaneous transluminal coro-
nary angioplasty.1 However, in-stent restenosis remains the
major limitation of coronary stent implantation.2 Previous his-
tological studies in human demonstrated that restenosis process
is characterized by acute inﬂammation and early thrombus for-
mation followed by neointimal tissue proliferation in the
chronic stage after coronary stent implantation.3 Another study
using serial intravascular ultrasound showed that stents did not
recoil and that in-stent restenosis was the result of exaggerated
neointimal tissue proliferation.4
Insulin resistance is one of the major characteristics of meta-
bolic syndromes related to obesity and obesity associated com-
plications such as type 2 diabetesmellitus, hypercholesterolemia
and cardiovascular disease.5 Insulin resistance with hyperinsuli-
nemia is associated with glucose intolerance, hypertension,
obesity and dyslipoproteinemias characterized by hypertriglyce-
ridemias or low high density lipoprotein cholesterol (HDL-C)
levels, which are well known risk factors for coronary artery dis-
eases.6 It has been reported that hyperinsulinemia is an indepen-
dent risk factor for ischemic heart disease,7 and induces greater
vascular smooth muscle cell (VSMC) proliferation in experi-
mental models.8
Leptin is an adipokine hormone which was shown to be
strongly correlated with body mass index (BMI), fat accumula-
tion and insulin resistance,9 insulin resistant individuals were
shown to have higher leptin concentrations than those who
are insulin sensitive, and independent of body fat mass.10 In
addition leptin has been recognized as an independent risk fac-
tor for coronary heart disease.11 Previous studies have demon-
strated different direct effects of leptin on vascular and
inﬂammatory cells responsible for promoting atherothrombo-
sis, particularly; it activates multiple signal transduction path-
ways in human monocytes and vascular cells.12 Leptin
receptors are expressed in human atherosclerotic lesions.13 Fur-
thermore, the prothrombotic effects of leptin might be mediated
by platelet leptin receptors.14 Moreover, leptin is emerged as a
metabolic hormone that contributes to the regulation of vascu-
lar biology and it modulates endothelial nitric oxide (NO)
synthesis.15
This study was planned to evaluate the relationship between
insulin resistance, insulin levels, leptin levels and coronaryin-stent restenosis after successful coronary stenting in non-dia-
betic patients with coronary heart disease, and to determine
their value in prediction of restenosis.
2. Patients and methods
This study was carried out in the Departments of Internal
Medicine, Cardiology and Clinical Pathology, Faculty of Med-
icine, Zagazig University. The study was conducted from Jan-
uary 2008 to December 2009.
The study included 48 non-diabetic patients (39 males and 9
females) with coronary heart disease (CHD) who came due to
recurrence of symptoms (chest pain) 6–9 months after success-
ful elective placement of intracoronary bare-metal stents. All
patients were subjected to 12 lead ECG, stress ECG and fol-
low-up coronary angiographic study to evaluate the cause of
recurrent chest pain. The patients were classiﬁed according
to the presence of intracoronary stent restenosis (deﬁned as
recurrence of stenosis by >50% reduction in the diameter of
the stented coronary segment) into two groups:
1. CHD patients with in-stent restenosis: It included 20
patients (16 males and 4 females) with a mean age of
51.75 ± 3.7 years, stenosis severity % at a follow-up of
72.25 ± 5.98 and minimal luminal diameter (MLD) at a
follow-up of 0.95 ± 0.28 mm.
2. CHD patients without in-stent restenosis: It included 28
patients (23 males and 5 females) with a mean age of
50.85 ± 3.4 years, stenosis severity % at a follow-up
of 19.6 ± 3.1 and MLD at a follow-up of 2.59 ± 0.4 mm.
All the patients included in the study were not diabetic
(FPG< 100 mg/dl) but on performing oral glucose tolerance
test (OGTT) 23 patients were shown to have impaired glucose
tolerance (IGT) (2-h postload glucose 140–199 mg/dl) and (25
patients) had normal glucose tolerance (NGT) (2-h postload
glucose <140 mg/dl), but all patients had normal fasting plas-
ma glucose levels <100 ng/dl.
The levels of normal FPG, IGT, NGT are according to the
American Diabetic Association (ADA).16
All patients gave informed consent to participate in the
study.
All the subjects were submitted to full clinical assessment
including history taking and through clinical examination
Table 1 Demographic and clinical data of the studied groups.
CHD patients with in-stent
restenosis (n= 20)
CHD patients without in-stent
restenosis (n= 28)
P
Age (year) 51.75 ± 3.7 50.85 ± 3.4 0.39
Male/female 16 (80%)/4 (20%) 23 (82%)/5 (18%) 0.89
BMI (kg/m2) 29.4 ± 1.2 29.3 ± 1.16 0.61
WHR 0.97 ± 0.02 0.96 ± 0.025 0.07
S.B.P (mmHg) 127.4 ± 9.0 124.8 ± 13.0 0.45
D.B.P (mmHg) 82.3 ± 6.0 79.7 ± 9.9 0.29
Hypertension, n (%) 8 (40%) 12 (42.9%) 0.84
IGT, n (%) 10 (50%) 13 (46.4%) 0.8
Dyslipidemia, n (%) 11 (55%) 14 (50%) 0.73
Oral antiplatelet drugs, n (%) 8 (40%) 12 (42.9%) 0.84
Hypolipidemic drugs
(statins), n (%)
11 (55) 14 (50%) 0.73
Table 2 Comparison of the laboratory parameters in the studied groups.
CHD patients with in-stent restenosis (n= 20) CHD patients without in-stent restenosis (n= 28) P
F. glucose (mg/dl) 92.9 ± 6.1 92.0 ± 5.3 0.6
2-hPP glucose (mg/dl) 145 ± 30.1 143.0 ± 29.4 0.82
F insulin (lU/ml) 12.57 ± 1.17 8.2 ± 1.2 <0.001*
Sum PP insulin (lU/ml) 204.7 ± 26.5 135.9 ± 23.1 <0.001*
HbA1c 5.5 ± 0.2 5.4 ± 0.26 0.1
HOMA-IR 2.9 ± 0.44 1.88 ± 0.37 <0.001*
Total cholesterol (mg/dl) 189.3 ± 25.6 187.1 ± 27.7 0.78
HDL-C (mg/dl) 55 ± 6.5 56.1 ± 7.3 0.7
LDL-C (mg/dl) 110.55 ± 18.9 107.75 ± 21.4 0.63
TG (mg/dl) 121.75 ± 14.9 117.3 ± 17.7 0.33
Leptin (ng/ml) 10.54 ± 1.63 6.6 ± 1.0 <0.001*
* P is signiﬁcant.
Table 3 Comparison of the angiographic parameters before and after stent implantation and at follow-up in the studied groups.
CHD patients with in-stent restenosis (n= 20) CHD patients without in-stent restenosis (n= 28) P
MLD (mm)
Before stent implantation 0.74 ± 0.28 0.76 ± 0.29 0.83
After stent implantation 2.85 ± 0.43 2.88 ± 0.41 0.78
At follow-up 0.95 ± 0.28 2.59 ± 0.4 <0.001*
Late lumen loss (mm) 1.9 ± 0.17 0.29 ± 0.14 <0.001*
Diameter stenosis %
Before stent implantation 83.7 ± 6.8 82.1 ± 6.75 0.43
After stent implantation 15.55 ± 3.44 14.86 ± 3.25 0.48
At follow-up 72.25 ± 5.98 19.6 ± 3.1 <0.001*
Number of stents
One stent, n (%) 14 (70%) 20 (71.4%) 0.91
Two stents, n (%) 6 (30%) 8 (28.6%) 0.91
* P is signiﬁcant.
Association of insulin resistance, insulin and leptin levels with coronary in-stent restenosis 37including blood pressure measurement, assessment of body
mass index (BMI) [weight (kg)/high (m2)] and waist to hip
ratio (WHR) [waist circumference (cm)/hip circumference
(cm)].
Laboratory measurements: Blood samples were collected
from all subjects after overnight fasting (12 h) for the following
investigations:Fasting plasma glucose (FPG), 2-h post-prandial blood glu-
cose (2-hPPG) levels, total cholesterol (T. cholesterol), high den-
sity lipoprotein cholesterol (HDL-C), triglyceride (TG) were
assessed by using anADVIA 1650 auto analyzer (SiemensMed-
ical Solutions Diagnostic, USA).
Low density lipoprotein cholesterol (LDL-C) was estimated
with the equation of Friedewald et al.17
Table 4 Correlation study of mean MLD at follow-up and some parameters of the study.
MLD
All patients (n= 48)
r P
F insulin (lU/ml) 0.49 <0.001*
Sum PP insulin (lU/ml) 0.6 <0.001*
HOMA-IR 0.63 <0.001*
Leptin (ng/ml) 0.55 <0.001*
* P is signiﬁcant.
















Fig. 1 Correlation between MLD and HOMA-IR.














Fig. 2 Correlation between MLD and leptin.
38 A. Shoukry et al.Fasting and post-prandial insulin concentrations were mea-
sured by chemiluminescence immunoassay using an imulite
analyzer (DPC, New York, USA) kit provided from diagnostic
products co-operation (Los Angeles, CA, USA). This assay is
a solid phase, two-site chemiluminescent methods immuno-
metric assay. The unlabeled antigen binds to the immobilized
antibody and is measured (in terms of quantity) after the la-
beled antibody is added.
Glycoselated hemoglobin (HbA1c) was estimated by ion ex-
change resin chromatography using Stanbio Glycohemoglobin.
After 12 h overnight fast, an oral glucose tolerance test
(OGTT) was made for all patients by giving a 75 g oral glucose
load, then blood samples were drawn from all patients after 1and 2 h of assessment of 1-h post-prandial insulin (1-hPP insu-
lin) and 2-h post-prandial insulin (2-hPP insulin) concentrations
and also 2-h post-prandial blood glucose (2-hPP glucose) levels
were evaluated.
The sum of 1-hPP insulin and 2-hPP insulin (sum PP insu-
lin) was calculated and taken as a measure of post-prandial
insulin concentrations.
Serum leptin was measured using a DRG leptin (sand-
wich) ELISA kit (Ruo, USA). The microtiter wells are coated
with monoclonal antibody directed toward a unique antigenic
site on a leptin molecule. An aliquot of patient sample contain-
ing endogenous leptin is incubated in the coated well with a
speciﬁc rabbit anti-leptin antibody. A sandwich complex is
formed. After incubation, the unbound material is washed
off and an antirabbit peroxidase conjugate is added for detec-
tion of the bound leptin. After addition of the substrate solu-
tion, the intensity of the color developed is proportional to the
concentration of leptin in the patient sample.
Insulin resistance (IR) was calculated with the formula of
homeostasis model assessment of IR (HOMA-IR) using the fol-
lowing equation: HOMA-IR = fasting plasma insulin (lU/
ml) · fasting plasma glucose (mmol/l)/22.5, the median insulin
resistance in normal subjects assessed by HOMA in a study
made by Matthews et al. was 1.21, 1.45, 1.96 in stressed fasting
samples, 1.3 in overnight basal samples and 2.0 inmorning basal
samples.18
2.1. Coronary angiography
Coronary angiography was performed through transfemoral
approach using the Seldinger technique.19 Coronary angiogra-
phy was performed at baseline, immediately after stenting and
6–9 months after stenting to detect in-stent restenosis in pa-
tients presented with recurrence of chest pain. All patients were
subjected to coronary angiography to evaluate the cause of
recurrence of symptoms.
The following parameters were assessed in the stented cor-
onary segment: minimal luminal diameter (MLD) and percent-
age of diameter stenosis and they were taken before and after
stent implantation and at follow-up. Also late lumen loss
(MLD after stent implantation minus MLD at follow-up)
was assessed.
2.2. Procedure of stent implantation
All patients in the study received 600 mg clopidogrel the day be-
fore the procedure and another 75 mg at the day of the proce-
dure and 10,000 units of unfractionated heparin at the
procedure. Angioplasty stent implantation was performed
Table 5 Correlation study between late loss of coronary lumen in the stented coronary segment and some parameters of the study.
Late loss
All patients (n= 48)
r P
F insulin (lU/ml) 0.98 <0.001*
Sum PP insulin (lU/ml) 0.7 <0.001*
HOMA-IR 0.67 <0.001*
Leptin (ng/ml) 0.72 <0.001*
* P is signiﬁcant.
















Fig. 3 Correlation between late loss and HOMA-IR.














Fig. 4 Correlation between late loss and leptin.
Table 6 Multiple regression analysis for predictors of in-stent
restenosis.
B ± S.E. P
F insulin 0.41 ± 0.02 <0.001*
Sum PP insulin 0.02 ± 0.003 <0.001*
HOMA-IR 1.5 ± 0.15 <0.001*
Leptin 0.3 ± 0.03 <0.001*
* P is signiﬁcant.
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approach either by direct stenting or after predilatation accord-
ing to the criteria of each individual lesion. All patients who
underwent coronary angiography were instructed to receive
clopidogrel 75 mg in addition to acetylsalicylic acid daily for
one year.
2.3. Statistical analysis
Results were entered, checked and analyzed using SPSS version
15.0 (statistical package for social science, SPSS Inc., Chicago,
USA). Continuous variables were expressed as means ± stan-
dard deviation (SD). Dichotomous, discrete or categorical
variables were expressed as percent. The unpaired Student’s t
test was used for comparison of means of the continuousvariables to evaluate differences between the two groups. The
chi-square (v2) test was used to compare categorical variables.
The correlation between variableswas done using Pearson’s cor-
relation coefﬁcient. Logistic multiple regression analysis was
used to determine the predictors of restenosis. Differences were
considered to be statistically signiﬁcant when the P values were
<0.05.
3. Results
Table 1 demographic and clinical data of the studied groups, age
andmale/female ratiowere comparable and did not signiﬁcantly
differ in CHD patients with in-stent restenosis as compared to
CHD patients without in-stent restenosis, also there was no sta-
tistical signiﬁcant difference between the two groups as regard to
BMI, WHR, SBP, DBP and percentage of patients who had
hypertension, IGT and dyslipidemia. The percentage of patients
taking oral antiplatelet drugs, antihypertensive drugs and hypo-
lipidemic drugs were comparable in both groups (P> 0.05).
There was a highly signiﬁcant increase in mean values of
FP insulin (12.57 ± 1.17 versus 8.2 ± 1.2, P< 0.001), sum
PP insulin (204.7 ± 26.5 versus 135.9 ± 23.1, P< 0.001),
HOMA-IR (2.9 ± 0.44 versus 1.88 ± 0.37, P< 0.001) and
leptin (10.54 ± 1.63 versus 6.6 ± 1.0, P< 0.001) in CHD
patients with in-stent restenosis when compared to CHD pa-
tients without in-stent restenosis but there was no signiﬁcant
difference between both groups in F glucose, 2-hPP glucose,
HbA1c, T. cholesterol, HDL-C, LDL-C and TG (P> 0.05)
(Table 2).
MLD at follow-up was signiﬁcantly lower in CHD pa-
tients with in-stent restenosis when compared to CHD pa-
tients without in-stent restenosis (0.95 ± 0.28 versus
2.59 ± 0.4, P< 0.001) while diameter stenosis% at follow-
up and late lumen loss were signiﬁcantly higher in patients
with restenosis when compared to patients without restenosis
[(72.25 ± 5.98 versus 19.6 ± 3.1, P< 0.001), (1.9 ± 0.17
versus 0.29 ± 0.14, P< 0.001), respectively], whereas there
40 A. Shoukry et al.was no signiﬁcant difference between the two groups as re-
gard to MLD and diameter stenosis % before and after
stent implantation (P> 0.05) (Table 3).
There was a highly signiﬁcant negative correlation between
MLD at follow-up and each of FP insulin (r= 0.49,
P< 0.001), sum PP insulin (r= 0.6, P< 0.001), HOMA-
IR (r= 0.63, P< 0.001) and leptin (r= 0.55, P< 0.001)
(Table 4, Figs. 1 and 2), whereas a positive correlationwas found
between late lumen loss and each of FP insulin (r= 0.98,
P< 0.001), sum PP insulin (r= 0.70, P< 0.001). HOMA-IR
(r= 0.67,P< 0.001) and leptin (r= 0.72,P< 0.001) (Table 5,
Figs. 3 and 4).Multiple regression analysis revealed that each of
FP insulin, sumPP insulin, HOMA-IR and leptin can be consid-
ered as an independent predictor of in-stent restenosis
(P< 0.001) (Table 6).4. Discussion
In-stent restenosis constitutes a signiﬁcant clinical problem
after coronary stent implantation and continues to limit the
long term success of the procedure. In this study we tried to
evaluate the relationship between insulin resistance, insulin lev-
els, leptin levels and in-stent coronary restenosis in non-dia-
betic patients with CHD. Insulin resistance is a state in
which peripheral tissues have decreased sensitivity to insulin
leading to increased circulating insulin levels to maintain
euglycemia. So, hyperinsulinemia is secondary to insulin resis-
tance. Hyperinsulinemia in non-diabetic individuals may be a
marker for a cluster of metabolic abnormalities including
hypertension, dysplipidemia and impaired insulin mediate glu-
cose uptake (impaired glucose tolerance),6 the later is a meta-
bolic state in which hyperinsulinemia is associated with normal
fasting blood glucose and is considered a risk factor of cardio-
vascular disease,20 HOMA-IR is the parameter that expresses
insulin resistance, our study revealed a highly signiﬁcant
increase in HOMA-IR in CHD patients with in-stent resteno-
sis as compared to CHD patients without in-stent restenosis
(2.9 ± 0.44 versus 1.88 ± 0.37, P< 0.001) this indicates that
patients with restenosis are more insulin resistant than patients
without restenosis, also our results revealed a negative correla-
tion between HOMA-IR and MLD at follow-up and a positive
correlation between HOMA-IR and late lumen loss. Our
results were supported by those obtained by Piatti et al.21
who found that patients with CHD and restenosis after a stent-
ing procedure were markedly insulin resistant and that insulin
resistance is an independent predictor of early restenosis after
coronary stenting, also Nishio et al.22 had suggested that the
cutoff value of HOMA-IR for restenosis after coronary stent-
ing is 2.0 and that insulin resistance is associated with the
increase in late lumen loss of stented coronary segment, and
MLD at follow-up was signiﬁcantly decreased in insulin resis-
tant group of CHD patients. Moreover, Lima-Filho et al.23
concluded that insulin resistance with HOMA-IR < 2.06
decreased the risk of restenosis. Some studies which were made
to evaluate the effect of metabolic syndrome (including IR) on
the risk of restenosis in drug eluting stents (DESs) implanted
recipients has shown that metabolic syndrome did not increase
restenosis rates after DESs implantation and that the recent
advent of DESs has signiﬁcantly reduced the incidence of
restenosis compared with bare-metal stents, both in non-dia-
betic and in diabetic patients.24Our results revealed a highly signiﬁcant increase in F insulin
and sum PP insulin (as a measure of post-prandial insulin con-
centrations) in CHD patients with in-stent restenosis and that
both F insulin and sum PP insulin levels were negatively corre-
lated with MLD at follow-up, whereas they were positively
correlated with late lumen loss of the coronary stent. Piatti
et al.21 had reported that both CHD patient groups (with
and without restenosis) were hyperinsulinemic after glucose
load, but insulin levels were markedly higher in patients with
restenosis. Moreover, Radke et al.25 demonstrated that fasting
plasma insulin levels serves as a valuable predictor of resteno-
sis after coronary stent implantation and patients with high
fasting insulin levels (>8 lU/ml) were characterized by a smal-
ler reference diameter of coronary vessels and developed a sig-
niﬁcantly higher late lumen loss. Moreover, Takagi et al.26 and
Babalik et al.27 have shown that the sum of immunoreactive
insulin (post-prandial hyperinsulinemia) during an OGTT
was the best predictor of increased neointimal tissue prolifera-
tion and was a strong predictor of restenosis at six month fol-
low-up after coronary stenting. Takagi et al.28 also reported
that the neointimal index measured by intracoronary ultra-
sound six months after coronary stenting was correlated with
fasting and post glucose load insulin levels. Also, follow-up
studies using intracoronary ultrasound showed that there
was a decrease of in-stent neointimal tissue proliferation and
intimal index measured by intracoronary ultrasound by almost
50% in patients with IGT by improving insulin sensitivity after
six months therapy using thiazolidinediones, pioglitazone or
rosiglitazone.29–31
The vascular effects of insulin are rather complex. Some of its
vascular effects are protective and induced through activation of
phosphatidyl inositol 3 kinase (PI3 K), production of cGMP32
and endothelial nitric oxide (NO).33 NO in turn can inhibit neo-
intimal hyperplasiawhich is dependent uponmigration and pro-
liferation of vascular smooth muscle cells (VSMCs) and also it
can attenuate binding of inﬂammatory cells to vascular wall, in-
hibit thrombosis by reducing platelet adhesion and aggregation
andmaintain vascular relaxation.34,35 Insulin has other vascular
effects which is hazardous, and occurs through stimulation of
mitogen activated protein kinase (MAPK) signaling pathway,
which in turn stimulates VSMCs proliferation and migration,
stimulates other vascular growth factors production and in-
creases endothelin-1 (a vasoconstrictor agent) production.33
During the state of insulin resistance, insulin signaling via
PI3 K is decreased, whereas the MAPK remains intact.36
Our ﬁndings revealed that plasma leptin levels were signiﬁ-
cantly increased in CHD patients with in-stent restenosis when
compared with CHD patients without in-stent restenosis, also
leptin was negatively correlated with MLD at follow-up and
positively correlatedwith late lumen, loss, our ﬁndingswere sup-
ported by those obtained from Piatti et al.21 who revealed that
leptin levels are increased in non-diabetic patients with resteno-
sis after stenting andNishio et al.22 found that concentrations of
leptin in the insulin resistant group were higher than those in the
non-insulin resistant group. Recently, Galluccio et al.37 found
that impaired leptin/adiponectin ratio and hyperinsulinemia
were reported in patientswith in-stent restenosis. Leptin is a hor-
mone related to fatmetabolism and IR, it has been recognized as
an independent risk factor for coronary heart disease and pro-
motes vascular remodeling and neointimal tissue proliferation
by induction of proliferation, differentiation of VSMCs. Multi-
ple regression analysis in our study revealed that each of insulin
Association of insulin resistance, insulin and leptin levels with coronary in-stent restenosis 41resistance, fasting and post-prandial hyperinsulinemia and
hyperleptinemia can be considered as a predictor of coronary
in-stent restenosis, so it is important to determine HOMA-IR,
fasting and PP hyperinsulinemia after an OGTT, and leptin lev-
els for non-diabetic CHD patients undergoing stent implanta-
tion to take a primary preventive strategies to decrease rate of
restenosis after stenting, from the therapeutic point of view
the group of CHD patients with insulin resistance, hyperinsuli-
nemia and hyperleptinemia should be considered a high risk
group and many measures should be taken to decrease insulin
resistance such as weight reduction which will be also beneﬁcial
in decreasing leptin levels, and also giving such patients insulin
sensitizers (pioglitazones, rosiglitazone) to improve insulin sen-
sitivity and decrease hyperinsulinemia. Moreover the stents
which are implanted in this group of patients should be eluted
with antiproliferative drugs which are effective in restenosis
prevention.5. Conclusion
The present study revealed that fasting and sum PP insulin lev-
els, HOMA-IR and leptin levels were signiﬁcantly increased in
CHD patients with in-stent restenosis and each of them was
negatively correlated with MLD at follow-up and positively
correlated to late lumen loss, our study, also suggests that insu-
lin resistance, fasting and post-prandial hyperinsulinemia and
hyperleptinemia are considered predictors of coronary in-stent
restenosis and evaluation of HOMA-IR, insulin levels after
standard OGTT and leptin levels are important tools in an at-
tempt to recognize subjects at a risk of early restenosis among
non-diabetic, CHD patients undergoing percutaneous coro-
nary revascularization and stent implantation.References
1. Schoming A, Kastrati A, Mudra H, et al. Four year experience
with Palmaz-Schatz stenting in coronary angioplasty complicated
by dissection with threatened or present vessel closure. Circulation
1994;90:2716–24.
2. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent
restenosis: current status and future strategies. J Am Coll Cardiol
2002;39:183–93.
3. Komatsu R, Ueda M, Noruko T, Kojima A, Becker AE.
Neointimal tissue response at site of coronary stenting in human:
macroscopic, histological and immunological analysis. Circulation
1998;98:224–33.
4. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and
mechanism of in-stent restenosis. A serial intravascular ultrasound
study. Circulation 1996;94:1247–54.
5. Mizuno T, Matsui H, Imamura A, Numaguchi Y, Sakai K,
Murohara T, et al. Insulin resistance increase circulating mal-
ondialdehyde-modiﬁed LDL and impairs endothelial function in
healthy young men. Int J Cardiol 2004;97:455–61.
6. Defronzo RA, Ferrannini E. Insulin resistance: a multifacted
syndrome responsible for NIDDM, obesity, hypertension, dysli-
pidemia, and atherosclerotic cardiovascular disease. Diabetes Care
1991;14:173–94.
7. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as
an independent risk factor for ischemic heart disease. N Engl J
Med 1996;334:952.
8. Pfeﬁle B, Dischuneit H. Effect of insulin on growth factors of
cultured human arterial smooth muscle cells. Diabetologia
1981;20:155–8.9. Zimmet P, Hodge A, Nicolson M, Staten M, de Courten M,
Moore J, et al. Serum leptin concentration, obesity and insulin
resistance in western cross sectional study. Br Med J
1996;313:965–9.
10. Segal KR, Landt M, Klein S. Relationship between insulin
sensitivity and plasma leptin concentration in lean and obese
men. Diabetes 1996;45:988–91.
11. Wallace AM,McMahon AD, Packard CJ, et al. Plasma leptin and
the risk of cardiovascular disease in the west of Scotland coronary
prevention study (Woscops). Circulation 2001;104:3052–6.
12. Parhami F, Tintut Y, Ballard A, Fogelman AM, Dermer LL.
Leptin enhances the calciﬁcation of vascular cells: artery wall as a
target of leptin. Circ Res 2001;88:954–60.
13. Kang SM, Know HM, Hong BK, Kim D, Kim IJ, Choi EY, et al.
Expression of leptin receptor (ob-R) in human atherosclerotic
lesions: potential role in intima neovascularization. Yonsei Med J
2000;41:68–75.
14. Bodari PF, Westrick RJ, Wickenheiser KJ, Shen Y. Eitzman DT:
effect of leptin on arterial thrombosis following vascular injury in
mice. JAMA 2002;287:1706–9.
15. Vecchione C,Maffei A, Colella S, et al. Leptin effect on endothelial
nitric oxide is mediated through AKT-endothelial nitric oxide
synthase phosphorylation pathway. Diabetes 2002;51:168–73.
16. American Diabetes Association (ADA). Diagnosis and classiﬁca-
tion of diabetes mellitus. Diabetes Care 2007;30:S42–7.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of lowdensity lipoprotein cholesterol in plasma,without
use of the preparative ultracentrifuge. Clin Chem 1978;18:499–502.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher
RC, Turner RC. Homeostasis model assessment: insulin resistance
and B-cell function from fasting plasma glucose and insulin
concentration in man. Diabetologia 1985;28:412–9.
19. Seldinger SI. Catheter replacement of the needle in percutaneous
arteriography, a new technique. Acta Radiol 1953;39:368.
20. Fuller JH, Shipley MJ, Rose G, Jarret RJ, Kween H. Coronary
heart disease risk and impaired glucose tolerance: the Whitehall
study. Lancet 1980;1:1373–6.
21. Piatti PM, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo
A, et al. Association of insulin resistance, hyperleptinemia and
impaired nitric oxide release with in-stent restenosis in patients
undergoing coronary stenting. Circulation 2003;108:2074–81.
22. Nishio K, Shigemitsu M, Kusuyama T, Fukui T, Kawamura K,
Itoh S, et al. Insulin resistance in non diabetic patients with acute
myocardial infarction. Cardiovasc Revasc Med 2006;7:54–60.
23. Lima-Filho MO, Figueiredo GL, Foss-Freitas MC, Foss MC,
Marin-Neto JA. Predictors of restenosis after percutaneous coro-
nary intervention using bare metal stents. A comparison between
patients with and without dysglycemia. Braz J Med Biol Res
2010;43(6):572–9.
24. Canibus P, Faloia E, Piva T, Mucai A, Serenelli M, Perna GP,
et al. Metabolic syndrome does not increase angiographic reste-
nosis rates after drug eluting stent implantation. Metabolism
2008;57(5):593–7.
25. Radke PW, Voswinkel M, Reith M, Kaiser A, Haager PK,
Hanrath P, et al. Relation of fasting insulin plasma levels to
restenosis after elective coronary stent implantation in patients
without diabetes mellitus. Am J Cardiol 2004;93:639–41.
26. Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda
Y, et al. Hyperinsulinemia during oral glucose tolerance test is
associated with increased neointimal tissue proliferation after
coronary stent implantation in non diabetic patients. J Am Coll
Cardiol 2000;36:731–8.
27. Babalik E, Gurmen T, Orhan L, Bulur H, Gulbaran M, Ersanli M,
et al. Increased secretion of insulin during oral glucose tolerance
test can be a predictor of stent restenosis in non diabetic patients.
Catheter Cardiovasc Interv 2003;58:306–12.
28. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T,
Morioka S, et al. Impact of insulin resistance on neointimal tissue
42 A. Shoukry et al.proliferation after coronary stent implantation: intravascular
ultrasound studies. J Diabetes Complications 2002;16:50–5.
29. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M,
Mizoguchi S, et al. Pioglitazone reduces neointtimal tissue prolif-
eration after coronary stent implantation in patients with type 2
diabetes mellitus: an intravascular ultrasound scanning study. Am
Heart J 2003;146:E5.
30. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Yang Y, et al.
Preventive effects of rosiglitazone on restenosis after coronary
stent implantation in patients with type 2 diabetes. Diabetes Care
2004;27:2654–60.
31. Rosmarakis ES, Falagas ME. Effect of thiazolidinediones therapy
on restenosis after coronary stent implantation: A meta-analysis of
randomized controlled trials. Am Heart J 2007;154:144–50.
32. Zhang S, Yang Y, Kone BC, Allen JC, Kahn AM. Insulin
stimulated cyclic guanosine monophosphate inhibits vascular
smooth muscle cell migration by inhibiting Ca/calmodulin-depen-
dent protein kinase II. Circulation 2003;107:1539–44.33. Piatti PM, Monti LD. Insulin resistance, hyperliptinemia and
endothelial dysfunction in coronary restenosis. Curr Opin Phar-
macol 2005;5:160–4.
34. Lefroy DC, Crake T, Uren NG, et al. Effects of inhibition of
nitric oxide synthesis on epicardial coronary artery caliber and
coronary blood ﬂow in humans. Circulation 1993;88:43–54.
35. Yao SH, Ober JC, Krishnaswami A, et al. Endogenous nitric oxide
protect against platelet aggregation and cyclic ﬂow variation in
stenosedandendothelium-injuredarteries.Circulation1992;86:1302–9.
36. Cusi K, Mesons K, Osman A, Pendergrass M, Patti ME,
Pratipanawatr T, et al. Insulin resistance differentially affects
the PI3-kinase and MAP kinase-mediated signaling in human
muscle. J Clin Invest 2000;105:311–20.
37. Galluccio E, Piatti P, Citterio L, Lucotti PC, Setola E, Cassina L,
et al. Hyperinsulinemia and impaired leptin–adiponectin ratio
associate with endothelial nitric oxide synthase polymorphism in
subjects with in-stent restenosis. Am J Physiol Endocrinol Metab
2008;294(5):E978–86.
